Evader Inc ( PINK: EVDR ), penny stock jumped more than 100 % with out specific news or announcements. Volumes are much stronger than daily average, Up move look convincing and stock might see further upside.
Our Call : Buy positions for Intraday trade, not to hold positions for even tomorrow.
Last news from the company was submission of a tender in the state of Tamil Nadu worth 110 million USD through its subsidiary Ascc Constructions.
Our Call : Buy positions for Intraday trade, not to hold positions for even tomorrow.
Last news from the company was submission of a tender in the state of Tamil Nadu worth 110 million USD through its subsidiary Ascc Constructions.
"A contract and emails providing a proof that a New York person Paul Ceglia was entitled a big stake in Facebook " was a fraud according to a CEO of Facebook Mark Zuckerberg. He declared under oath that he has neither signed a contract nor wrote any related emails.
He asked a federal judge to order Ceglia to immediately turn over the alleged original contract and emails, and for permission to inspect Ceglia's computers.
"Zuckerberg and Ceglia never discussed Facebook and they never signed a contract concerning Facebook," the filing said. "The contract is a cut-and-paste job, the emails are complete fabrications, and this entire lawsuit is a fraud."
Christopher "Kip" Hall, a partner at DLA Piper representing Ceglia, did not immediately return requests for comment.
Thursday's filing escalates the stakes as Ceglia, a wood pellet salesman from Wellsville, New York, tries to show he contracted in 2003 for 50 percent of Zuckerberg's interest in what became Facebook, which is privately held.
Forbes magazine in March estimated Zuckerberg's net worth at $13.5 billion. Analysts have said Facebook could be worth $70 billion should it go public, perhaps in 2012.
In Thursday's filing, Zuckerberg acknowledged signing an agreement with Ceglia, but that it concerned work Zuckerberg did for StreetFax.com, a website that posted photographs of traffic intersections for use in the insurance industry.
Zuckerberg hopes to use forensic testing on Ceglia's documentation. "When this testing confirms that all of these documents are forgeries, this lawsuit will end," he said.
Emails in Question
Ceglia sued last July, saying he made a contract with Zuckerberg for an 84 percent Facebook stake.
After he changed law firms, Ceglia filed a complaint that discussed the alleged contract and emails from 2003 and 2004 when Zuckerberg was a student at Harvard University.
In a Feb. 2, 2004 email discussed in the complaint, Zuckerberg was said to have resisted a clause that could have given Ceglia a stake greater than 80 percent, and instead suggested "that we officially return to 50/50 ownership."
Zuckerberg said forensic examiners reviewed his Harvard email account and found none of the alleged emails.
He also called Ceglia allegedly forgetting about the contract for seven years "incredible on its face," and recounted his prior run-ins with law enforcement.
This included an instance in 2009 when New York Attorney General Andrew Cuomo accused Ceglia of fraud and shut his business.
Separately, Cameron and Tyler Winklevoss are appealing to the U.S. Supreme Court a ruling that upheld their $65 million settlement with Facebook, which they accused of stealing their idea for the website. The twin brothers have said they were shortchanged in the 2008 accord.
The case is Ceglia v. Zuckerberg et al, U.S. District Court, Western District of New York, No. 10-00569.
( Source: CNBC )
( Source: CNBC )
Spherix Incorporated ( NASDAQ: SPEXD ), company announced positive data from its drug candidate SPX-106 in reducing Serum Triglycerides in Preclinical Testing. Stock skyrocketed more than 48 % to $ 5.
Our Call: Buy position may be initiated for trade at this levels.
Below is the News Release:
Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions in Serum Triglycerides in Preclinical Testing
 |
| Spherix Incorporated |
SPX-106 is one of five small molecules licensed by Spherix last year. In early 2011, Spherix initiated the preclinical development of SPX-106 and D-tagatose as a treatment for hypertriglyceridemia. In the recently completed study, treatment of animals using combination therapy with twice-daily oral dosing significantly reduced triglycerides by 43 mg/dl compared with control animals with a mean triglyceride level of 118 mg/dl (p=0.01). The same therapy significantly reduced total cholesterol by 73 mg/dl from a mean level of 378 mg/dl compared with control animals (p=0.01).
SPX-106 is in preclinical development in combination with other agents, including D-tagatose, for the prevention and treatment of atherosclerosis, hypertriglyceridemia and related dyslipidemias. The Company has initiated development of SPX-106 and D-tagatose as a treatment for hypertriglyceridemia, and plans to start an initial human efficacy study in the fourth quarter of 2011 or the first quarter of 2012.
"Spherix has toxicology, preclinical, clinical and other studies underway, and the findings of this preclinical study advance our understanding of the effects of SPX-106 and D-tagatose on triglycerides and cholesterol," said Dr. Claire Kruger, Chief Executive Officer of Spherix. "The market for triglyceride-lowering drugs exceeds $3 billion annually in the U.S. alone, and we believe that, should our studies be successful, there will be an important role for SPX-106 to play in the treatment regimen."
In December 2010, the Company signed a research contract with a leading global contract research organization (CRO) to investigate the role of SPX-106 and D-tagatose in lowering triglycerides. Work will continue through at least 2012. In the first phase of this program, the Company is working with the CRO to design and execute studies in cell culture, animal models and humans to clarify the mechanism of action of SPX-106 and D-tagatose in modulating triglycerides in the metabolic syndrome.
About Spherix
Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research. The Company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is dedicated to developing and licensing/marketing proprietary therapeutic products for treatment of diabetes, metabolic syndrome and atherosclerosis. Biospherics is actively seeking a pharmaceutical partner to continue the development of its Phase 3 compound for the treatment of diabetes, D-tagatose, while exploring new drugs and combinations for treatment of high triglycerides, a risk factor for atherosclerosis, myocardial infarction and stroke. Spherix's Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products and industrial chemicals and pesticides. For more information, please visit www.spherix.com.
Forward-Looking Statements
This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of D-tagatose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop D-tagatose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
SOURCE Spherix Incorporated
ATLANTIC CITY, New Jersey - Resorts Casino Hotel, which raised some hackles this year with a bare-derriere billboard to promote a show, is taking things even further in a bid to win back business.
The casino's new owners held a grand reopening to unveil the skimpy new flapper costumes that got them sued this year by female cocktail servers fired after being deemed not sexy enough wearing them.
And the casino announced it will host a nightly adults-only Naked Circus in a parking lot tent starting in July. Actually, it is only mostly naked, much like New York's Naked Cowboy, but you get the idea.
"It'll be as naked as the law allows," said Resorts co-owner Dennis Gomes, who is fast gaining a reputation in the casino industry because of his willingness to push sex to promote his brand and generate publicity and buzz.
His son Aaron Gomes said the female performers will wear pasties and G-strings.
Dennis Gomes says it all is designed to win back millions of dollars in business the casino lost under previous owners that nearly closed it late last year.
Resorts posted a $5.3 million operating loss in the first quarter of this year, but Gomes and co-owner Morris Bailey, a New York real estate investor, are pumping large amounts of promotional cash into the casino to try to rebuild its customer base after buying it last December at a steep discount.
The Naked Circus show, which will start on the July 4th holiday weekend, will be one of three daily circuses that Resorts will host in Atlantic City, the second-largest U.S. gambling market after Las Vegas, Nevada.
The casino also unveiled its new flapper costumes, which cocktail servers will wear from now on. They are the costumes that resulted in a lawsuit from 15 servers fired in March after an outside panel hired by Resorts deemed them insufficiently sexy in the new garb.
The lawsuit is pending.
The black-fringed flapper dresses, worn with black fishnet stockings, are extremely low-cut in the back. Billboards that Resorts put up around town and on the side of its building show two models wearing them with part of their rear ends exposed, and it is obvious they are not wearing undergarments. (Servers on hand for the May 27 announcement were.)
"Sexiness is just part of it," Gomes said. "It's excitement, fun. Everything that Las Vegas has, we're going to have."
Gomes, who made national headlines for letting customers play tic-tac-toe against a chicken when he ran Atlantic City's Tropicana Casino and Resort, is bringing a new slant on that promotion to Resorts: "The Tic-Tac-Toe-Playing Chick."
"There will be this woman, and customers can play tic-tac-toe against her," Gomes said. "If they win, they get $5,000."
The ceremony was held a day after the 33rd anniversary of Resorts' opening in 1978 as the nation's first casino outside Nevada.
Copyright 2011 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Economic Headlines for June 3 2011 ( Friday ) :
1) The pace of growth in the U.S. services sector picked up slightly in May after a sharp drop in the previous month, according to an industry report released Friday.
The Institute for Supply Management said its services sector index rose to 54.6 last month from 52.8 in April. The reading came in just above economists' forecasts for 54.0, according to a Reuters survey. The bounce came after April's reading fell to the lowest level since August 2010.
2) New hiring from US employers was far less than expected as high energy prices and Japan's quake effect dampened new hiring. Jobless rate rose to 9.1 percent, Nonfarm payrolls increased 54,000 last month, the weakest reading since September, the Labor Department said on Friday.
Private employment rose just 83,000, the least since last June, while government payrolls dropped 29,000. Economists had expected payrolls to rise 150,000 and private hiring to increase 175,000 in May.
The government revised employment figures for March and April to show 39,000 fewer jobs created than previously estimated.
Sino Forest Corp ( PINK: SNOFF ), stock plunged ore than 77% in last two trading session after analyst Muddy Waters Research released an investigative report and investors have dumped all the holdings Read More.
Groupon, Online Coupon company filed for Initial Public Offering ( IPO ) in a latest series of social networking site IPOs offerings to tap US capital markets. Company will trade under the ticker of GRPN but price range and exchange was not disclosed.
Groupon filed to raise up to $750 million in its IPO. However that figure is preliminary and could change.
In April, a source told Reuters that Groupon could raise as much as $1 billion in the IPO, which could value the fast-growing daily deals site at $15 billion to $20 billion.
A string of hot Internet companies including Facebook and Twitter have received multibillion-dollar valuations, raising questions about how these companies, albeit fast-growing, could justify the sky-high valuations.
Other Internet companies including LinkedIn Corp and China's Renren Inc have had strong IPO debuts in recent months, causing speculation that other companies would rush to follow.
Underwriters are being led by Morgan Stanley and Goldman Sachs.
"While we're looking forward to being a public company," said CEO Andrew D. Mason in a letter to potential stockholders. "We intend to continue operating according to the long-term focused principles that have gotten us to this point."
The letter also hints that the company is looking forward to "agressively investing in growth."
( Source: Reuters )
( Source: Reuters )
EntreMed Inc ( NASDAQ: ENMD ), stock of the company jumped more than 42 %, without specific news or announcements from the company.Traders might keep an eye on the stock as some news development might be announced.
Our Call: Cautious trade, Wait for news before buying stock
Our Call: Cautious trade, Wait for news before buying stock
Orexigen Therapeutics Inc ( NASDAQ: OREX) plunges more than 30 % and touched a 52 week low as FDA committee is not convinced to approve its experimental obesity drug without additional heart safety trials data.
Below is the detailed news:
Orexigen Therapeutics said on Friday that it would explore opportunities for its products outside the United States after failing to sway U.S. regulators from their demands for a heart safety study before approving the company's experimental obesity drug.
The company said, after a recent meeting with the Food and Drug Administration, that the FDA would not consider approving the drug, Contrave, for a narrower population with lower cardiovascular risk without data from the heart outcomes trial.
Orexigen also said its proposed heart study was rejected by the agency.
The FDA rejected Contrave earlier this year, dealing a severe blow to what stood to be the first new diet pill in a decade and crippling Orexigen's shares.
Orexigen said on Friday that it would appeal the latest FDA decisions through a resolution process, saying the agency's request for the heart outcomes trial was "unprecedented and would generate significantly more information than is necessary or feasible."
According to Orexigen, the FDA plans to hold a general advisory committee meeting early next year to discuss cardiovascular assessment for obesity therapeutics.
Meanwhile, Orexigen said it would put on hold any further development for its obesity programs in the United States "until a clear and feasible path to regulatory approval is identified." It will also speed up exploration of opportunities for its product candidates outside the United States.
( Source: Reuters)
Mahindra Satyam, a leading global consulting and IT services provider, and MasterCard®, today announced the establishment of a Center of Excellence for testing in Kuala Lumpur, Malaysia. The center will provide support for global testing for MasterCard business applications, as well as application development in Java and Business Intelligence.
"At MasterCard®, our focus as a company is to deliver innovative products and solutions for our customers and cardholders, and we look for the best organizations to help us deliver on this commitment," said Sheryl Andrasko, Group Executive, MasterCard® Worldwide. "We believe that working with Mahindra Satyam will enable us to continue deliver on these goals to meet the global needs of these key stakeholder groups." she continued.
Mahindra Satyam's Testing Center of Excellence for MasterCard® will support the company's efforts around research and development, and facilitate global collaboration.
"Establishing this Center of Excellence connotes the beginning of a valued relationship with MasterCard®" said Lakshmanan Chidambaram, Senior Vice President – Sales & Operations, Mahindra Satyam.
Through this collaboration, Mahindra Satyam intends to leverage its proven expertise of testing in credit card functionalities and automated process to enhance the customer and cardholder experience for MasterCard® around the world.
